SEC Filings

S-8
MEDTRONIC PLC filed this Form S-8 on 12/08/2017
Entire Document
 
Document



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
_____________________________
Medtronic Public Limited Company
(Exact Name of Registrant as Specified in Its Charter)
_____________________________
 
Ireland
(State or Other Jurisdiction of
Incorporation or Organization)
98-1183488
(I.R.S. Employer
Identification No.)
 
 
20 On Hatch, Lower Hatch Street
Dublin 2, Ireland
(Address of principal executive offices)
_____________________________

Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan
(Full Title of the Plan)
_____________________________
Martha Ha, Esq.
Medtronic Public Limited Company
c/o Medtronic, Inc.
710 Medtronic Parkway
Minneapolis, Minnesota 55432
(763) 514-4000
(Name, address and telephone number, including area code, of agent for service)
_____________________________
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
x
 
Accelerated filer
¨
Non-accelerated filer
¨
(do not check if a smaller reporting company)
Smaller reporting company
¨
 
 
 
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨            
_____________________________





CALCULATION OF REGISTRATION FEE

Title of Securities
To Be Registered
Amount
To Be
Registered (1)
Proposed
Maximum
Offering Price
Per Share
Proposed
Maximum
Aggregate
Offering Price
Amount Of
Registration Fee
Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan
50,000,000
$80.52 (2)
$4,026,000,000.00
$501,237.00

(1
)
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional ordinary shares, nominal par value $0.0001 per share (“Ordinary Shares”) of Medtronic Public Limited Company (the “Company”) which may become issuable under the plans covered by this Registration Statement by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Company’s outstanding Ordinary Shares.
(2
)
Estimated solely for the purpose of calculating the registration fee. This registration fee has been calculated pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act, based upon the average of the high and low prices of the Ordinary Shares on December 5, 2017 as reported by the New York Stock Exchange, which was $80.52.






STATEMENT OF INCORPORATION BY REFERENCE
This registration statement on Form S-8 (this “Registration Statement”) is being filed to register an additional 50,000,000 ordinary shares, nominal par value $0.0001 per share (“Ordinary Shares”), of Medtronic Public Limited Company (the “Company” or the “Registrant”) issuable under the Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan (formerly the Medtronic, Inc. 2013 Stock Award and Incentive Plan) (the “2013 Plan”). In accordance with General Instruction E to Form S-8, this Registration Statement on Form S-8 incorporates by reference the contents of Registration Statement on Form S-8, File No. 333- 201737, filed on January 28, 2015 relating to an aggregate of 154,359,469 Ordinary Shares to be authorized for issuance under certain of the Company’s plans (including 68,308,770 Ordinary Shares under the 2013 Plan), except to the extent supplemented, amended or superseded by the information set forth herein.  

PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 5.
Interests of Named Experts and Counsel
The validity of the Ordinary Shares to be issued under this Registration Statement has been passed upon by A&L Goodbody.

Item 6.
Indemnification of Directors and Officers
Pursuant to the Company’s memorandum and articles of association, subject to the provisions of, and so far as may be permitted by the Irish Companies Act, 2014, every director and secretary of the Company shall be indemnified out of the assets of the Company against all costs, losses, expenses and liabilities incurred by him or her in the execution and discharge of his or her duties or in relation thereto including any liability incurred by him or her in defending civil or criminal proceedings which relate to anything done or omitted or alleged to have been done or omitted by him or her as an officer or employee of the Company and in which judgment is given in his or her favor (or the proceedings are otherwise disposed of without any finding or admission of any material breach of duty on his or her part) or in which he or she is acquitted or in connection with any application under any statute for relief from liability in respect of any such act or omission in which relief is granted to him or her by the court.
Pursuant to the Company’s memorandum and articles of association and so far as may be permitted by the Irish Companies Act, 2014, every current or former executive or officer (other than any director) or any person who is serving or has served at the request of the Company as a director, executive, officer or trustee of another company shall be indemnified out of the assets of the Company against expenses, including attorneys’ fees, judgments, fines, and amounts paid in settlement actually and reasonably incurred by him or her in connection with any threatened, pending, or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the Company, to which he or she was, is, or is threatened to be, made a party by reason of the fact that he or she is or was such a director, executive, officer or trustee.
Effective January 26, 2015, the Company entered into deeds of indemnification (the “Deeds of Indemnification”) with its directors and corporate secretary. The Deeds of Indemnification provide indemnification to such directors and the corporate secretary to the fullest extent permitted by the laws of Ireland, and in accordance with the Company’s memorandum and articles of association, for all expenses and other amounts actually incurred in any action or proceeding in which the director or corporate secretary is or may be involved by reason of the fact that he or she is or was a director or corporate secretary of the Company or otherwise serving the company or other entities at the company’s request, on the terms and conditions set forth in the Deeds of Indemnification. Further, the Company agrees, to the fullest extent permitted by the laws of Ireland, to advance expenses incurred in defense of these proceedings, on the terms and conditions set forth in the Deeds of Indemnification. The Deeds of Indemnification also provide procedures for requesting and obtaining indemnification and advancement of expenses.
The foregoing summary is qualified in its entirety to the terms and provisions of such arrangements.









Item 8.
Exhibits

Exhibit No.
 
Description
3.1
 
3.2
 
4.1
 
4.2
 
5.1
 
23.1
 
23.2
 
Consent of A&L Goodbody (included in Exhibit 5.1)
24.1
 
Power of Attorney (included on signature page)*
*
Filed herewith





SIGNATURES
Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Minneapolis, Minnesota, on December 8, 2017.
 
Medtronic Public Limited Company
(registrant)

 
By:
/s/ Bradley E. Lerman
 
 
Name:
Bradley E. Lerman
 
 
Title:
Senior Vice President,
General Counsel & Corporate Secretary






Each person whose signature appears immediately below constitutes and appoints Bradley E. Lerman, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same with all exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on December 8, 2017.
Signature
 
 
 
Title
 
 
 
/s/ Omar Ishrak
Omar Ishrak
 
 
 
Chairman and Chief Executive Officer (principal executive officer)
 
 
 
/s/ Karen L. Parkhill
Karen L. Parkhill
 
 
 
Executive Vice President and Chief Financial Officer (principal financial and accounting officer)
 
 
 
/s/ Richard H. Anderson
 
 
 
Director
Richard H. Anderson
 
 
 
 
 
 
 
/s/ Scott C. Donnelly
 
 
 
Director
Scott C. Donnelly
 
 
 
 
 
 
 
/s/ Shirley Ann Jackson, Ph.D.
 
 
 
Director
Shirley Ann Jackson, Ph.D.
 
 
 
 
 
 
 
/s/ Michael O. Leavitt
 
 
 
Director
Michael O. Leavitt
 
 
 
 
 
 
 
/s/ James T. Lenehan
 
 
 
Director
James T. Lenehan
 
 
 
 
 
 
 
/s/ Elizabeth G. Nabel
 
 
 
Director
Elizabeth G. Nabel
 
 
 
 
 
 
 
/s/ Denise M. O’Leary
 
 
 
Director
Denise M. O’Leary
 
 
 
 
 
 
 
/s/ Kendall J. Powell
 
 
 
Director
Kendall J. Powell
 
 
 
 
 
 
 
/s/ Robert C. Pozen
 
 
 
Director
Robert C. Pozen
 
 
 
 
 
 
 
/s/ Craig Arnold
 
 
 
Director
Craig Arnold
 
 
 
 
 
 
 
/s/ Randall J. Hogan, III
 
 
 
Director
Randall J. Hogan, III
 
 
 
 






 
Authorized Representative in the United States:
 
By:
/s/ Bradley E. Lerman
 
 
Name:
Bradley E. Lerman
 
 
Title:
Senior Vice President,
General Counsel & Corporate Secretary



s8opinionfinal
PM Law • CE Gill • EM FitzGerald • JG Grennan • J Coman • PD White • VJ Power • LA Kennedy • SM Doggett • B McDermott • C Duffy • PV Maher • S O’Riordan • MP McKenna • KA Feeney M Sherlock • EP Conlon • E MacNeill • KP Allen • EA Roberts • C Rogers • G O’Toole • JN Kelly • N O’Sullivan • MJ Ward • AC Burke • D Widger • C Christle • S O’Croinin • JW Yarr • DR Baxter A McCarthy • JF Whelan • JB Somerville • MF Barr • AM Curran • A Roberts • M Dale • RM Moore • D Main • J Cahir • M Traynor • PM Murray • N Ryan • P Walker • K Furlong • PT Fahy • M Rasdale D. Inverarity • M Coghlan • DR Francis • A Casey • B Hosty • M O’Brien • K Killalea • L Mulleady • K Ryan • E Hurley • G Stanley • D Dagostino • E Keane • C Clarkin • R Grey • R. Lyons • J Sheehy • C Morrissey C McLoughlin • C Carroll • SE Carson • P Diggin • J Williams • A O’Beirne • MD Cole • G Conheady • J Dallas • SM Lynch • M McElhinney Consultants: SW Haughey • Professor JCW Wylie • AF Browne • MA Greene • AV Fanagan • JA O’Farrell • IB Moore A&L Goodbody Solicitors Dublin International Financial Services Centre Belfast 25-28 North Wall Quay, Dublin 1 London D01 H104 New York T +353 1 649 2000 San Francisco Dx: 29 Dublin | www.algoodbody.com Palo Alto Date 8 December 2017 Our Ref 01413513 Medtronic plc 20 On Hatch Lower Hatch Street Dublin 2 Ireland Medtronic plc (the Company) Dear Sirs We act as Irish Counsel for the Company, a public limited company incorporated under the laws of Ireland, in connection with the proposed registration by the Company of 50,000,000 ordinary shares of the Company, nominal value $0.0001 per share (the Ordinary Shares), issuable under the Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan (the Plan) pursuant to a Registration Statement on Form S-8 (the Registration Statement) to be filed by the Company under the Securities Act of 1933, as amended. In connection with this Opinion, we have reviewed copies of such corporate records of the Company as we have deemed necessary as a basis for the opinion hereinafter expressed. In rendering this opinion, we have examined and have assumed the truth and accuracy of the contents of such documents and certificates of officers of the Company and of public officials as to factual matters and have conducted such searches in public registries in Ireland as we have deemed necessary or appropriate for the purposes of this opinion but have made no independent investigation regarding such factual matters. In our examination we have assumed the truth and accuracy of the information contained in such documents, the genuineness of all the signatures, authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies and the authenticity of the originals of such documents. We have further assumed: 1 that none of the resolutions and authorities of the shareholders or directors of the Company upon which we have relied have been varied, amended or revoked in any respect or have expired and that the Ordinary Shares will be issued in accordance with such resolutions and authorities; 2 that at each time Ordinary Shares will be issued, the Company will then have sufficient authorised but unissued share capital to allow for the issue of such Ordinary Shares and that the Ordinary Shares will be issued in accordance with the Plan; 3 that the Company will receive consideration equal to the aggregate of the nominal value and any premium required to be paid up on the Ordinary Shares issued pursuant to awards under the Plan and that such consideration will be in cash and/or otherwise provided in accordance with Irish law; and 4 the absence of fraud on the part of the Company and its respective officers, employees, agents and advisors.


 
2 Having made such further investigation and reviewed such other documents as we have considered requisite or desirable, subject to the foregoing and to the within qualifications and assumptions, and provided that the Registration Statement, as finally amended, has become effective, we are of the opinion that; 1 the Ordinary Shares have been duly authorised and when issued, in accordance with the Registration Statement, the Plan and the options or other equity awards granted or to be granted thereunder will, be validly issued, fully paid and not subject to calls for any additional payments (“non-assessable”) (except for Ordinary Shares issued pursuant to deferred payment arrangements, which shall be fully paid upon the satisfaction of such payment obligations); 2 the obligations of the Company under the Plan have been duly authorised by all necessary corporate action on behalf of the Company; 3 in any proceedings taken in Ireland for the enforcement of the Plan, the choice of Minnesota State law as the governing law of the contractual rights and obligations of the parties under the Plan would be upheld by the Irish Courts unless it were considered contrary to public policy, illegal, or made in bad faith. In rendering this opinion we have confined ourselves to matters of Irish law. We express no opinion on any laws other than the laws of Ireland (and the interpretation thereof) in force as at the date hereof. We hereby consent to the filing of this Opinion with the United States Securities and Exchange Commission as an exhibit to the Registration Statement. Yours faithfully A&L Goodbody M-38460763-3


 
Exhibit


Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated June 27, 2017 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in Medtronic plc’s Annual Report on Form 10‑K for the year ended April 28, 2017.
/s/ PricewaterhouseCoopers LLP

Minneapolis, MN
December 4, 2017



X